Improvements in or relating to detection of salmonella
CA 2248171 A1 · Owner: Unilever Plc · Inventors: Metcalfe, Mark Andrew; Berry, Mark John; Parry, Steven H.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed is an immunoglobulin molecule or antigen-binding variant thereof which binds to an epitope present within amino acid residues 403 to 452 of the flagellin protein of Salmonella typhimurium PIR accession No. A24262 or the, equivalent portion from other Salmonella strains together with, inter alia, use thereof, and an assay device comprising the antibody.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 22, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 22, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 22, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.